Assembly Financial Statements From 2010 to 2026

ASMB Stock  USD 26.80  2.57  8.75%   
Assembly Biosciences' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Assembly Biosciences' valuation are provided below:
Gross Profit
-24.7 M
Profit Margin
(1.04)
Market Capitalization
464.5 M
Enterprise Value Revenue
6.3119
Revenue
37.2 M
We have found one hundred twenty available fundamental signals for Assembly Biosciences, which can be analyzed and compared to other ratios and to its rivals. All investors should make sure to validate all of Assembly Biosciences prevailing market performance against the performance between 2010 and 2026 to make sure the company can sustain itself down the road. The current year's Market Cap is expected to grow to about 168.1 M, whereas Enterprise Value is forecasted to decline to about 50.9 M.

Assembly Biosciences Total Revenue

34.44 Million

Check Assembly Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Assembly Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 245 K, Interest Expense of 544.1 K or Selling General Administrative of 17.8 M, as well as many indicators such as Price To Sales Ratio of 3.63, Dividend Yield of 0.0 or PTB Ratio of 1.56. Assembly financial statements analysis is a perfect complement when working with Assembly Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Assembly Stock
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.

Assembly Biosciences Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets130.8 M137 M133.8 M
Slightly volatile
Short and Long Term Debt Total4.9 M2.8 M8.8 M
Slightly volatile
Other Current Liabilities6.5 M10.5 M6.6 M
Slightly volatile
Total Current Liabilities57.7 M55 M19.8 M
Slightly volatile
Property Plant And Equipment NetM3.9 MM
Slightly volatile
Accounts Payable639.1 K672.8 K2.1 M
Slightly volatile
Cash36.9 M44.1 M37.4 M
Slightly volatile
Non Current Assets TotalM4.2 M25 M
Very volatile
Non Currrent Assets Other340.9 K358.8 K977.9 K
Pretty Stable
Cash And Short Term Investments100.8 M128.9 M104.3 M
Slightly volatile
Common Stock Total Equity59.2 K56.4 K30.3 K
Slightly volatile
Common Stock Shares Outstanding7.3 M6.9 M2.9 M
Slightly volatile
Liabilities And Stockholders Equity130.8 M137 M133.8 M
Slightly volatile
Non Current Liabilities Total60.9 M34.2 M129.9 M
Slightly volatile
Other Current Assets2.6 M3.5 M2.8 M
Slightly volatile
Other Stockholder EquityB988.4 M518.4 M
Slightly volatile
Total Liabilities103.6 M98.7 M42.4 M
Slightly volatile
Property Plant And Equipment GrossM3.9 MM
Slightly volatile
Total Current Assets103.8 M132.8 M107.5 M
Slightly volatile
Short Term Debt394.2 K414.9 K2.4 M
Slightly volatile
Common Stock7.6 K8.1 K16.6 K
Very volatile
Property Plant EquipmentM854.5 K983.5 K
Slightly volatile
Net Tangible Assets107.5 M95.1 M92.7 M
Slightly volatile
Capital Surpluse975.6 M929.1 M513.3 M
Slightly volatile
Other Liabilities2.3 M2.5 M13.1 M
Slightly volatile
Current Deferred Revenue45.4 M43.3 M13.2 M
Slightly volatile
Net Receivables342 K360 K1.6 M
Slightly volatile
Net Invested Capital28.5 M30 M118.5 M
Slightly volatile
Net Working Capital115.3 M60.9 M123.3 M
Very volatile
Capital StockK6.3 K24.3 K
Slightly volatile
Capital Lease ObligationsM2.8 M9.2 M
Slightly volatile

Assembly Biosciences Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization245 K148.3 K244.6 K
Slightly volatile
Selling General Administrative17.8 M20.7 M18.3 M
Slightly volatile
Other Operating Expenses64.9 M85 M67.3 M
Slightly volatile
Research Development44.4 M64.3 M46.4 M
Slightly volatile
Total Operating Expenses55.2 M85 M57.9 M
Slightly volatile
Net Interest Income6.7 M6.4 M2.6 M
Slightly volatile
Interest Income6.7 M6.4 M2.6 M
Slightly volatile
Reconciled Depreciation110.3 K116.1 K317.1 K
Pretty Stable
Extraordinary Items6.9 M7.7 M8.4 M
Slightly volatile
Selling And Marketing Expenses360 K405 K442.1 K
Slightly volatile

Assembly Biosciences Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.4 M3.6 M8.2 M
Very volatile
Begin Period Cash Flow34.5 M22.8 M34.7 M
Slightly volatile
Depreciation245 K148.3 K244.6 K
Slightly volatile
Capital Expenditures30.6 K32.2 K523.6 K
Pretty Stable
Total Cash From Financing Activities43.5 M33.9 M42.7 M
Very volatile
End Period Cash Flow36.9 M44.1 M37.4 M
Slightly volatile
Sale Purchase Of Stock670.8 K706.1 K35.6 M
Slightly volatile
Net Borrowings494.7 K552.1 K478 K
Slightly volatile
Change To Netincome15.8 M11.6 M13.1 M
Slightly volatile
Issuance Of Capital Stock43.8 M26.4 M99.8 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio3.633.8258.4616
Slightly volatile
Days Sales Outstanding5.595.8954.0929
Slightly volatile
Average Payables1.2 MM1.8 M
Slightly volatile
Stock Based Compensation To Revenue0.120.130.8085
Slightly volatile
Capex To Depreciation0.240.252.4056
Pretty Stable
EV To Sales2.282.452.9615
Slightly volatile
Payables Turnover10095.4733.8498
Slightly volatile
Sales General And Administrative To Revenue0.540.571.9316
Pretty Stable
Research And Ddevelopement To Revenue1.681.774.7581
Pretty Stable
Capex To Revenue8.0E-49.0E-40.0873
Pretty Stable
Cash Per Share20.3921.4753.3164
Slightly volatile
Days Payables Outstanding3.763.963.3 K
Slightly volatile
Intangibles To Total Assets0.310.170.3177
Slightly volatile
Current Ratio2.642.789.2196
Slightly volatile
Receivables Turnover38.3564.1737.2036
Slightly volatile
Capex Per Share0.0040.00420.1796
Pretty Stable
Revenue Per Share6.935.465.5076
Very volatile
Interest Debt Per Share0.560.597.2909
Slightly volatile
Debt To Assets0.02830.02980.4217
Slightly volatile
Days Of Payables Outstanding3.763.963.3 K
Slightly volatile
Ebt Per Ebit0.961.01188.8 K
Slightly volatile
Quick Ratio2.642.789.2244
Slightly volatile
Net Income Per E B T0.610.910.8394
Slightly volatile
Cash Ratio0.880.925.5206
Slightly volatile
Days Of Sales Outstanding5.595.8954.0929
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.081.150.9922
Pretty Stable
Fixed Asset Turnover9.059.788.9685
Slightly volatile
Debt Ratio0.02830.02980.4217
Slightly volatile
Price Sales Ratio3.633.8258.4616
Slightly volatile
Asset Turnover0.230.220.0961
Slightly volatile

Assembly Biosciences Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap168.1 M85.3 M214.6 M
Very volatile
Enterprise Value50.9 M53.5 M178.9 M
Very volatile

Assembly Fundamental Market Drivers

Assembly Upcoming Events

27th of March 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
27th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Assembly Biosciences Financial Statements

Assembly Biosciences stakeholders use historical fundamental indicators, such as Assembly Biosciences' revenue or net income, to determine how well the company is positioned to perform in the future. Although Assembly Biosciences investors may analyze each financial statement separately, they are all interrelated. For example, changes in Assembly Biosciences' assets and liabilities are reflected in the revenues and expenses on Assembly Biosciences' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Assembly Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue43.3 M45.4 M
Total Revenue32.8 M34.4 M
Cost Of Revenue148.3 K140.9 K
Stock Based Compensation To Revenue 0.13  0.12 
Sales General And Administrative To Revenue 0.57  0.54 
Research And Ddevelopement To Revenue 1.77  1.68 
Revenue Per Share 5.46  6.93 
Ebit Per Revenue(1.83)(1.92)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Assembly Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Assembly Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Assembly Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Assembly Biosciences Stock:
Check out the analysis of Assembly Biosciences Correlation against competitors.
For information on how to trade Assembly Stock refer to our How to Trade Assembly Stock guide.
You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Assembly Biosciences. If investors know Assembly will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Assembly Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(4.60)
Revenue Per Share
4.319
Quarterly Revenue Growth
0.576
Return On Assets
(0.16)
Return On Equity
(0.37)
The market value of Assembly Biosciences is measured differently than its book value, which is the value of Assembly that is recorded on the company's balance sheet. Investors also form their own opinion of Assembly Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Assembly Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Assembly Biosciences' market value can be influenced by many factors that don't directly affect Assembly Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Assembly Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Assembly Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Assembly Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.